IntoCell, Inc. (287840.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩15,980 (-0.75%) as of
Key statistics
- Market cap
- 240.05B
- Dividend yield
- 0.00%
- 52-week range
- 13,050.00 – 74,900.00
- Revenue (TTM)
- 3.19B
- Profit margin
- -295.93%
- Volume
- 22.76k
About IntoCell, Inc.
IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Daejeon, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.